VIT-2763 is an oral small-molecule inhibitor of ferroportin. It displaces TMR-hepcidin from ferroportin with an IC50 of 24 nM. It also ameliorates anemia, enhances erythropoiesis, and reduces organ iron loading in the Hbbth3/+ β-thalassemia intermedia disease model.

Zunsemetinib(ATI-450, CDD-450) is a selective inhibitor of p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) that mediates inflammatory responses. It reduces inflammation in cryopyrinopathy, alleviates arthritis, and potentially prevents tachyphylaxis.

VIT-2763 is an oral small-molecule inhibitor of ferroportin. It displaces TMR-hepcidin from ferroportin with an IC50 of 24 nM. It also ameliorates anemia, enhances erythropoiesis, and reduces organ iron loading in the Hbbth3/+ β-thalassemia intermedia disease model.

VIT-2763 is an oral small-molecule inhibitor of ferroportin. It displaces TMR-hepcidin from ferroportin with an IC50 of 24 nM. It also ameliorates anemia, enhances erythropoiesis, and reduces organ iron loading in the Hbbth3/+ β-thalassemia intermedia disease model.

VIT-2763 is an oral small-molecule inhibitor of ferroportin. It displaces TMR-hepcidin from ferroportin with an IC50 of 24 nM. It also ameliorates anemia, enhances erythropoiesis, and reduces organ iron loading in the Hbbth3/+ β-thalassemia intermedia disease model.

L-AP4 (L-APB) is a potent and specific agonist for the group III mGluRs, with EC50s of 0.13, 0.29, 1.0, 249 μM for mGlu4, mGlu8, mGlu6 and mGlu7 receptors, respectively.

Helenalin is an anti-inflammatory sesquiterpene lactone. Helenalin selectively inhibits transcription factor NF-κB by directly targeting p65. Helenalin has alkylating activity, targets the cysteine sulfhydryl groups in the p65 subunit of NF-κB, thereby inhibits its DNA binding.

ZD7288 (ICI D7288) is a selective hyperpolarization-activated cyclic nucleotide-gated (HCN) channel blocker.

(R)-CPP is a highly potent NMDA receptor antagonist.

Vaborbactam (RPX7009) is a cyclic boronic acid pharmacophore β-lactamase inhibitor.